Morgan Stanley Dbv Technologies S.A. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Dbv Technologies S.A. stock. As of the latest transaction made, Morgan Stanley holds 632,463 shares of DBVT stock, worth $531,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares

632,463

Previous 659,726 4.13%

Holding current value

$531,268

Previous $626,000 24.28%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.75 - $0.95 $20,447 - $25,899	-27,263 Reduced 4.13%	632,463 $474,000
Q4 2023 Feb 13, 2024	BUY	$0.7 - $1.33 $94,521 - $179,591	135,031 Added 25.74%	659,726 $626,000
Q3 2023 Nov 15, 2023	SELL	$1.3 - $1.88 $10,479 - $15,154	-8,061 Reduced 1.51%	524,695 $713,000
Q2 2023 Aug 14, 2023	BUY	$1.42 - $2.23 $11,049 - $17,351	7,781 Added 1.48%	532,756 $1.01 Million
Q1 2023 May 15, 2023	BUY	$1.28 - $1.73 $37,295 - $50,407	29,137 Added 5.88%	524,975 $887,000

Q4 2022 Feb 14, 2023	SELL	$1.16 - $1.8 $41,668 - $64,657	-35,921 Reduced 6.76%	495,838 $758,000
Q3 2022 Nov 14, 2022	SELL	$1.77 - $2.76 $79,260 - $123,592	-44,780 Reduced 7.77%	531,759 $941,000
Q2 2022 Oct 27, 2022	BUY	$1.15 - $3.25 $18,880 - $53,358	16,418 Added 2.93%	576,539 $1.47 Million
Q2 2022 Aug 15, 2022	BUY	$1.15 - $3.25 $18,880 - $53,358	16,418 Added 2.93%	576,539 $1.47 Million
Q1 2022 Oct 27, 2022	SELL	$1.22 - $1.77 $20,029 - $29,059	-16,418 Reduced 2.85%	560,121 $890,000
Q1 2022 May 13, 2022	SELL	$1.22 - $1.77 $398,882 - $578,706	-326,953 Reduced 36.86%	560,121 $890,000
Q4 2021 Feb 14, 2022	SELL	$1.39 - $5.58 $769,447 - $3.09 Million	-553,559 Reduced 38.42%	887,074 $1.42 Million
Q3 2021 Nov 15, 2021	BUY	$4.71 - $5.92 $6.79 Million - $8.53 Million	1,440,633 New	1,440,633 $7.06 Million

Others Institutions Holding DBVT

# of Institutions

Shares Held

37.7M

Call Options Held

Put Options Held

View Full List

About DBV Technologies S.A.

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $158M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

More about DBVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account